NovoCure Limited (NVCR)

NASDAQ: NVCR · IEX Real-Time Price · USD
15.63
+0.99 (6.76%)
At close: Mar 28, 2024, 4:00 PM
15.64
+0.01 (0.06%)
After-hours: Mar 28, 2024, 7:56 PM EDT

Total Valuation

NovoCure has a market cap or net worth of $1.69 billion. The enterprise value is $1.38 billion.

Market Cap 1.69B
Enterprise Value 1.38B

Important Dates

The next estimated earnings date is Thursday, May 2, 2024, before market open.

Earnings Date May 2, 2024
Ex-Dividend Date n/a

Share Statistics

NovoCure has 107.09 million shares outstanding. The number of shares has increased by 1.65% in one year.

Shares Outstanding 107.09M
Shares Change (YoY) +1.65%
Shares Change (QoQ) +0.13%
Owned by Insiders (%) 1.67%
Owned by Institutions (%) 85.89%
Float 95.92M

Valuation Ratios

PE Ratio n/a
Forward PE 909.09
PS Ratio 3.32
Forward PS 3.07
PB Ratio 4.67
P/FCF Ratio n/a
PEG Ratio -0.47
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 2.70
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.78, with a Debt / Equity ratio of 1.64.

Current Ratio 5.78
Quick Ratio 5.56
Debt / Equity 1.64
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage 5.66

Financial Efficiency

Return on equity (ROE) is -51.60% and return on invested capital (ROIC) is -24.29%.

Return on Equity (ROE) -51.60%
Return on Assets (ROA) -17.90%
Return on Capital (ROIC) -24.29%
Revenue Per Employee $350,542
Profits Per Employee -$142,493
Employee Count 1,453
Asset Turnover 0.44
Inventory Turnover 3.80

Taxes

In the past 12 months, NovoCure has paid $15.30 million in taxes.

Income Tax 15.30M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -72.94% in the last 52 weeks. The beta is 0.41, so NovoCure's price volatility has been lower than the market average.

Beta (1Y) 0.41
52-Week Price Change -72.94%
50-Day Moving Average 14.94
200-Day Moving Average 20.57
Relative Strength Index (RSI) 56.92
Average Volume (30 Days) 1,382,672

Short Selling Information

The latest short interest is 5.54 million, so 5.17% of the outstanding shares have been sold short.

Short Interest 5.54M
Short Previous Month 5.64M
Short % of Shares Out 5.17%
Short % of Float 5.78%
Short Ratio (days to cover) 5.25

Income Statement

In the last 12 months, NovoCure had revenue of $509.34 million and -$207.04 million in losses. Loss per share was -$1.95.

Revenue 509.34M
Gross Profit 381.06M
Operating Income -232.87M
Pretax Income -191.74M
Net Income -207.04M
EBITDA -221.90M
EBIT -232.87M
Loss Per Share -$1.95
Full Income Statement

Balance Sheet

The company has $912.36 million in cash and $596.24 million in debt, giving a net cash position of $316.12 million or $2.95 per share.

Cash & Cash Equivalents 912.36M
Total Debt 596.24M
Net Cash 316.12M
Net Cash Per Share $2.95
Equity / Book Value 362.50M
Book Value Per Share 3.38
Working Capital 855.29M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$73.34 million and capital expenditures -$27.09 million, giving a free cash flow of -$100.43 million.

Operating Cash Flow -73.34M
Capital Expenditures -27.09M
Free Cash Flow -100.43M
FCF Per Share -$0.94
Full Cash Flow Statement

Margins

Gross margin is 74.81%, with operating and profit margins of -45.72% and -40.65%.

Gross Margin 74.81%
Operating Margin -45.72%
Pretax Margin -37.64%
Profit Margin -40.65%
EBITDA Margin -43.57%
EBIT Margin -45.72%
FCF Margin -19.72%

Dividends & Yields

NovoCure does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -1.65%
Shareholder Yield -1.65%
Earnings Yield -12.24%
FCF Yield -5.94%
Dividend Details

Analyst Forecast

The average price target for NovoCure is $48.56, which is 210.69% higher than the current price. The consensus rating is "Buy".

Price Target $48.56
Price Target Difference 210.69%
Analyst Consensus Buy
Analyst Count 9
Revenue Growth Forecast (5Y) 10.64%
EPS Growth Forecast (5Y) -7.21%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

NovoCure has an Altman Z-Score of 0.76 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 0.76
Piotroski F-Score 1